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A B S T R A C T
In Norway, the management strategy for fetal and neonatal alloimmune thrombocytopenia (FNAIT) has for more
than two decades differed from most other countries. The focus of this paper is to describe and discuss the
Norwegian FNAIT management program. We recommend antenatal IVIg to women who previously have had a
child with FNAIT-induced ICH, and usually not to HPA-1a alloimmunized pregnant women where a previous
child had FNAIT, but not ICH. When deciding management strategy, we use not only the obstetric history but
also the antenatal anti-HPA-1a antibody level as a tool for risk stratification. The Norwegian National Unit for
Platelet Immunology (NNUPI) at the University Hospital of North Norway in Tromsø provides diagnostic and
consulting service for the clinicians and the blood banks all over the country, and serves as a national reference
laboratory for FNAIT investigations.
1. Introduction
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is typi-
cally suspected in a term-born neonate where widespread petechiae or
other signs of bleeding develop shortly after birth, in the absence of any
other condition known to be associated with neonatal thrombocyto-
penia. Thrombocytopenia in FNAIT is mainly due to maternal anti-
bodies against human platelet antigen (HPA)-1a. Occasionally, FNAIT is
suspected during fetal life due to ultrasound findings such as in-
trauterine fetal death, intracranial haemorrhage (ICH), isolated ven-
triculomegaly or extracranial haemorrhage in the fetus. The main
clinical concern with FNAIT is ICH. A growing number of reports also
describe links between maternal HPA-1a alloimmunization and reduced
birth weight, and intrauterine growth restriction risk has been sug-
gested to be another effect of HPA-1a alloimmunization [1,2]. The
frequency of ICH due to FNAIT is reported in 1:10,000 newborns [3], a
number which may be an underestimate of the true incidence, since it is
well documented that FNAIT is an underdiagnosed condition [4,5] and
diagnostics of FNAIT is only available in few places.
The high recurrence risk of severe FNAIT in subsequent pregnancies
[6] has urged several preventive strategies. As there is currently no
screening program introduced to identify the 2 % HPA-1a negative
pregnant Caucasian women at risk of having a child with FNAIT,
primary prevention has not been an option. Secondary prevention is
only possible when the risk of FNAIT is known before the child is born.
There is no international consensus regarding the antenatal manage-
ment for these high-risk pregnancies. Clinical guidelines vary between
countries and even between different hospitals. Most women known to
be HPA-1a-immunized are treated off-label with weekly high-dose in-
travenous immunoglobulin (IVIg) during pregnancy. Gestational age for
starting this treatment as well as the dose varies, but generally the
treatment starts during the second trimester and 1 g/kg/week is a
commonly used dose [7]. Some centres stratify the treatment according
to the presence or absence of ICH in the previous child and when ICH
occurred, i.e., early or late in pregnancy or perinatally. Recently a
systematic review compared different antenatal treatment strategies
[8]. This review proposed that first line antenatal management in
FNAIT is weekly IVIg administration, with or without the addition of
corticosteroids. Despite the widespread use of this treatment modality,
solid evidence for the efficacy of IVIg in preventing severe FNAIT is
lacking [8,9].
In Norway, the FNAIT management strategy has for more than two
decades differed from most other countries, since IVIg is only rarely
used in the management of HPA-1a-immunized women. The
“Norwegian FNAIT model” has puzzled many colleagues in other
countries, and some have even mentioned concern regarding the safety
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of our antenatal management strategy. Norway, being a small Nordic
country, maintains the Nordic welfare model with universal health care
and a comprehensive social security system. Norway has had the
highest Human Development Index ranking in the world since 2009.
Understanding why we do not offer antenatal IVIg as a standard therapy
in the context of HPA-1a alloimmunization is perhaps not easy and
deserves to be explained. The focus of this paper is therefore to describe
the Norwegian FNAIT management program, followed by a discussion
of the strategy.
2. The Norwegian FNAIT management model
2.1. Clinical follow-up
In HPA-1a-immunized pregnant women where a previous child had
FNAIT, but not ICH, IVIg is usually not given. Instead, immunized
women are closely monitored throughout the pregnancy. Maternal anti-
HPA-1a antibody levels are measured using a quantitative Monoclonal
Antibody-specific Immobilization of Platelet Antigens (MAIPA) assay
[10] every 4th week starting from 28 gestational weeks until delivery. If
anti-HPA-1a antibody levels reach 3 IU/mL or higher at any time point,
we recommend repetitive ultrasonographic examinations to look for
signs of fetal intra- or extracranial haemorrhage as well as fetal growth
assessments.
Since 2014 the National clinical guidelines for obstetricians in
Norway changed to recommending antenatal IVIg to women who pre-
viously have had a child with FNAIT-induced ICH. This change was
based on some evidence of reduced risk of fetal/neonatal ICH in sub-
sequent pregnancies by administration of IVIg when an older sibling
suffered from ICH [2]. The current recommendation is to start IVIg
treatment around 20 weeks of gestation at 1 g/kg/week until delivery.
Women with high anti-HPA-1a antibody levels during pregnancy
(≥ 3 IU/mL) are delivered by elective caesarean section (CS) at around
gestational week 38–39 in hospitals with a neonatal intensive care unit
as well as HPA-1a negative platelets available for the newborn in need.
If the woman previously had a child with ICH and has very high anti-
HPA-1a antibody levels during the subsequent pregnancy, a slightly
earlier delivery, around 37 weeks is considered.
Platelet count is measured from cord blood immediately after de-
livery, and prompt transfusion is given, typically starting within 30min
after birth. The current threshold to offer neonatal platelet transfusion
is platelet count is< 35×109/L. We also recommend to scan the
baby’s head by ultrasonography to rule out ICH in all cases of severe
FNAIT (i.e. platelet count ≤ 50× 109/L), even if the neonate shows no
clinical signs of haemorrhage. See Fig. 1 for an overview of the clinical
follow-up algorithm.
In pregnancies where the father is heterozygous (HPA-1ab) or not
typed, determination of fetal HPA-1 type can preclude unnecessary
follow-ups and interventions. Non-Invasive Prenatal Testing (NIPT) for
HPA-1 can be performed using cell-free fetal DNA in maternal
circulation [11–13]. A NIPT test for fetal HPA-1 typing is currently
under validation at the Norwegian National Unit for Platelet Im-
munology (NNUPI) but will require approval from the Norwegian
Health Authorities prior to clinical use.
2.2. The Norwegian National Unit for Platelet Immunology (NNUPI)
Since 1995, the NNUPI at the University Hospital of North Norway
in Tromsø has provided national diagnostic and consulting service for
the clinicians and the blood banks when FNAIT or other platelet anti-
body-mediated conditions have been suspected, serving as a national
reference laboratory for FNAIT investigations. Furthermore, NNUPI
also provides compatible antigen-negative platelet concentrates to pa-
tients. The Immunology Research Group at UiT The Arctic University of
Norway in Tromsø has had a close collaboration with NNUPI for many
years on FNAIT research.
NNUPI performs around 50 FNAIT-related investigations per year,
including thrombocytopenia in the newborn, follow-up of HPA-al-
loimmunized women during subsequent pregnancies, follow-up of non-
immunized HPA-1bb pregnant women, as well as referrals after sus-
pected ICH detected during fetal ultrasound examinations. It is well
known that FNAIT is severely under-diagnosed in Norway in the non-
screening setting [4].
2.3. Laboratory FNAIT assessments
A set of laboratory analyses is required to support FNAIT diagnosis
in a newborn with thrombocytopenia, with two central aims: con-
firmation of incompatibility in a platelet antigen between mother and
newborn and detection of maternal antibodies against antigen ex-
pressed on neonatal platelets. The algorithm for investigations has been
modified in line with availability of tests and recommendations, and the
current strategy is outlined in Fig. 2.
To do full FNAIT investigation analyses, we request 10mL of per-
ipheral blood (EDTA) from both the mother and the father, in addition
to 2−3mL peripheral blood or cord blood, depending on availability
from the newborn, taken at the time of delivery or as soon as FNAIT is
suspected. The initial tests aim to quickly assess if FNAIT is the diag-
nosis, and to provide compatible platelet transfusions when necessary.
A flow cytometric cross-match of maternal plasma with neonatal/pa-
ternal and HPA-defined panel platelets by indirect Platelet Immuno
Fluorescence Test (PIFT) is performed [14], as well as direct PIFT to
detect any in vivo-bound antibodies on neonatal platelets and exclude
autoantibodies on maternal/paternal platelets that would interfere with
test results. In addition, HPA-1a phenotyping of maternal platelets by
flow cytometry [15] is performed immediately, since anti-HPA-1a al-
loantibodies is the by far most common cause of FNAIT in Norway. All
these tests can be performed within hours to rapidly guide selection of
blood components. HPA-1bb blood components can be provided on
short notice; mainly platelet concentrates for the newborn but also red
Fig. 1. Algorithm for clinical follow-up during pregnancy of HPA-1a alloimmunized women with a prior obstetric history of FNAIT.
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cell concentrates, if necessary, for the mother. HPA-1bb platelet con-
centrates are also available as shelf-product at the Norwegian National
Advisory Unit of Immunohematology at Oslo University Hospital.
HPA genotyping in HPA-1, -2, -3.-5 and -15 systems is also routinely
performed as part of the investigations, with the possibility of extended
typing for HPA-4, HPA-6 and -9 in case of non-conclusive reactivity
patterns or non-Caucasian individuals.
For a complete and conclusive FNAIT investigation, maternal
plasma is tested for glycoprotein-specific antibodies in a MAIPA
screening assay with neonatal and/or paternal platelets and platelet
from blood donors with defined reactivity against gpIIb/IIIa, gpIb/IX,
gpIa/IIa, CD109 and HLA class I [16]. HPA-specificity in most cases is
determined by MAIPA, while quantitative MAIPA [17,18] is used to
determine the levels of anti-HPA-1a when detected.
If the MAIPA assay is negative, a commercial bead-based test for
anti-platelet antibodies Pak Lx (Immucor, Georgia, USA) is used as an
additional test before excluding the presence of anti-HPA antibodies. If
no anti-HPA antibodies are detected in Pak Lx either, we conclude that
there is no HPA-alloimmunization.
Other platelet-reactive antibodies (anti-HLA, anti-A/ anti-B or anti-
CD36 or private antigens) can also give a positive cross-match.
Although there is still no clear understanding whether anti-HLA class I
antibodies may cause severe thrombocytopenia in the newborn
[19–23], we perform a more detailed analysis of the HLA antibodies,
when maternal anti-HLA class I antibodies are the sole reactive anti-
bodies. It is then essential to show whether the neonate express the
cognate HLA class I antigens. Maternal anti-HLA antibody specificity is
determined by LIFECODES Single Antigen LSA Class I assay (Immucor)
and HLA class I genotyping of the neonate is performed by LIFECODES
HLA SSO RAPID assays for HLA-A, -B and –C (Immucor).
Some HPA-1bb pregnant women without obstetric history of FNAIT
are previously HPA typed in connection to blood and/or platelet do-
nation or during the previous HPA-1 screening program [24] These
women are tested for HLA-DRB3*01:01 and for those found to be po-
sitive, we strongly recommend testing for anti-HPA-1a antibodies in
gestational weeks 20 and 34 in line with the Norwegian national
guidelines. If anti-HPA antibodies are detected, we recommend follow-
up by MAIPA every 4th week from gestational week 28. Anti-HPA-1a
antibodies are quantified if present, while other specificities are re-
tested in subsequent samples. For women found to be HLA-
DRB3*01:01-negative we inform that the risk of HPA-1a alloimmuni-
zation and FNAIT is low, but we still offer antibody testing if the clin-
ician judge this is necessary. In addition, we recommend measuring the
platelet count of the newborn in order to be able to transfuse the child
immediately in those rare case where the platelet count is low despite
the mother being HLA-DRB3*01:01 negative.
In emergencies the results are communicated immediately to the
clinicians, followed by a written report from all laboratory analyses and
interpretational comments. This includes recommendations for follow-
up in subsequent pregnancies as well as recommendations of suitable
future blood components for the alloimmunized woman, if necessary.
An information letter is also sent to the mother.
3. Discussion
Our current FNAIT management strategy has been tested out in a
large prospective screening and intervention study, where the man-
agement strategy was found to be clearly beneficial in terms of reducing
risk of ICH and intrauterine fetal death as compared to historic pro-
spective controls [24]. Our strategy is therefore evidence-based, at least
in a screening setting. However, there may be a selection bias for more
severe FNAIT cases in the current non-screening setting.
Compared to how most Western countries manage pregnancies
where the risk of FNAIT is known before birth, Norway differs in two
important ways: first, we rarely use antenatal IVIg. Second, instead of
purely using obstetric history as risk predictor, we add the antenatal
anti-HPA-1a antibody level as a predictor when deciding management
strategy. Whether or not maternal anti-HPA-1a antibody levels influ-
ence the severity of neonatal alloimmune thrombocytopenia has been
disputed by some [25,26]. However, a recent systematic review of the
available literature concluded that there is an association between
maternal anti-HPA-1a antibody level and neonatal platelet count, both
when assessed prospectively and retrospectively, but with some ac-
knowledged limitations [27]. The cut-off antibody level of 3 IU/mL that
we currently use to stratify risk and intervention in these pregnancies is
based on prospective data [28], and we practice the same cut-off in a
non-screening setting. Improvements in antibody analysis and in-
creasing knowledge about different properties and subtypes of anti-
HPA-1a antibodies [29,30] may have potential for a more targeted and
individualized management strategy.
Our reluctance towards off-label use of IVIg to all HPA-1a alloim-
munized pregnant women is not mainly due to high-cost or the fact that
IVIg has side-effects [31–33]. We are more concerned of the lack of
evidence of a clinically relevant preventive effect when used in all HPA-
1a alloimmunized women. The Norwegian cohort of HPA-1a alloim-
munized pregnancies where the mother did not receive antenatal IVIg
may reflect the natural history of FNAIT regarding the neonatal out-
come. If high-dose IVIg treatment is effective in preventing ICH, one
would expect a poorer neonatal outcome in Norway as compared to
other Western countries. For this reason, we have initiated a study
where we evaluate all Norwegian non-IVIg-treated HPA-1a alloimmu-
nized pregnancies during the last 20 years assessing neonatal outcome.
Fig. 2. Algorithm for laboratory analysis in
FNAIT investigations.
At least two serological tests, including solid-
phase assays for antibody analysis of maternal
plasma. PIFT, Platelet Immune-Fluorescence
test, MAIPA; Monoclonal Antibody-specific
Immobilization of Platelet Antigens. Pak Lx is a
commercial bead-based test for anti-platelet
antibodies.
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The efficacy of antenatal IVIg treatment has not yet been evaluated in a
randomized placebo-controlled clinical trial. Whether it is ethically
acceptable to conduct a placebo-controlled clinical trial of IVIg for this
condition is also questionable [9]. The Norwegian cohort of non-se-
lected non-IVIg treated HPA-1a alloimmunized pregnancies may hence
serve as an important control group when evaluating the effect of IVIg.
The Norwegian management strategy includes delivery by elective
cesarean section (CS) 1–2 weeks prior to term, in pregnancies where the
risk of FNAIT is considered high. This risk assessment is mainly based
on anti-HPA-1a antibody levels. Whether or not CS prevents FNAIT-
associated ICH is still unsettled, but we cannot disregard that the mode
of delivery may have contributed to the good neonatal outcome of the
previous screening- and intervention study [24]. Data from the NOICH
study showed that most ICH cases happened before delivery [2], thus
questioning the need of CS to prevent ICH. However, the NOICH ICH
data were based on retrospective cases, and thus prone to selection bias.
Clearly more data are needed to settle this issue. In Norway we have
decided to continue this delivery strategy until more data concerning
the safety of vaginal birth for these pregnancies are available. There are
clear benefits of having a planned day-time delivery for the multi-dis-
ciplinary team around the patient, as well as having compatible platelet
concentrates ready for the newborn, if needed.
Several Western countries are currently considering implementation
of a screening program to identify pregnancies at risk of FNAIT. It is an
open question what antenatal management regimen should be applied
to all HPA-1a negative pregnant women where anti-HPA-1a antibodies
are detected during pregnancy – especially when a previous obstetric
history of FNAIT is missing to guide risk assessment. The Norwegian
FNAIT experience should therefore be part of management considera-
tions in a screening setting.
The current Norwegian FNAIT guidelines are continuation of the
management principals with positive experience from the previous
large screening study. Differences in health culture between Norway
and other Western countries may also explain different management
strategies, for instance regarding risk assessment and management.
Norwegian obstetricians being more prone to having natural vaginal
birth compared to American obstetricians is an interesting example of
cultural differences [34]. Litigation practice in obstetrics in Norway is
still relatively «sober», although there is an increasing pressure toward
minimizing all risks associated with pregnancy and delivery.
In conclusion, we will still practice a restrictive use of antenatal IVIg
as long as solid evidence of effect is lacking regarding use in all HPA-1a
alloimmunized pregnancies. We will also continue to monitor closely
the clinical outcomes of FNAIT while working toward implementation
of antenatal HPA-1a screening that will certainly reduce the burden of
FNAIT.
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